Poor EBRT responders (HRCTV > 30cc) warrants IC+ISBT from 1st fraction. Outcome of 141 LACC pts from TMH. 👍🏼 doi.org/10.1016/j.brac…

Chemo-radiation in high risk endometrial cancer - Institutional results published in South Asian J Cancer.

10-years results of FAST-forward trial: ✅ 26 Gy/5fx not inferior to standard 40/15fx ✅ No difference in ipsilateral breast recurrence, nor OS ✅ No difference in late TOX 26Gy/5fx new SOC for breast cancer, chest wall and partial breast adj RT. #ESTRO25

🔥⚡️🚀Adjuvant RT after cystectomy in high-risk bladder cancer: •25–30% LRR despite chemo •Safe (<5% G3–4 toxicity, 3 RCTs) •RT ↓ LRR = worthy goal Presented by Dr. Vedang Murthy Murthy at #ESTRO2025 #BladderCancer #Radiotherapy #OncoTwitter

Bounce (defined as an increase > 0.2 ng/mL) following ultra hypofrac #radiotherapy, is frequent (36%) & associated with improved prognosis. Data from HYPO RT PC at #ESTRO25 Possible bias (bounces by definition have a decrease in PSA after the rise) role of 3y landmark analysis

🔥⚡️🚀 First prospective comparison of SBRT vs HDR-BT in prostate cancer (SHERBET study): SBRT shows superior long-term efficacy & lower BCF. Two-fraction HDR-BT w/o ADT? Only in trials for intermediate-risk pts. Great work from Sunnybrook team! #RadOnc #GU25 Dr. Andrew Loblaw

Hope this would soon be the SOC for nodal fields too shortly, saving #outofpocketexpenses, #carbonsavings .One should give credit to Prof John Yarnold who STARTed this revolution in breast hypofractionation. #HYPORTtrial TMC Radiation Oncology Tata Medical Center

🚀 oustanding presentation by Vedang Murthy showing that #AUGMENTED RT ⬆️ outcomes with extremely limited tox in high-risk PCa #ESTRO2025

Big news from #ESTRO25! Nivolumab + CRT shows striking improvement in MIBC outcomes for patients not undergoing RC! BCFFS: 70.3% vs 43.4% OS at 2y: 86.8% vs 60.5% (p=0.005) Well tolerated + good onc outcomes = a game-changer? Time for Phase III trial! #TMT #MIBC #immunotherapy

Isotoxic FLAME shows 15% BCR difference with 10 years follow up with significant difference in local and regional recurrence #ESTRO2025 Amar Kishan

PORTEC 4a results . High risk benefits from EBRT ( only 25% had LND) and low risk has small but non inferior difference in vaginal recurrence with VBT DrKamrava Andrew Keller

Salvage post-RP SABR #POPART results presented by Federica Ferrario Stefano Arcangeli #ESTRO25 ✅Post-op SABR is safe ✅Post-op SABR preserves QoL ✅Further FU needed to confirm clinical outcomes 📰Similar results published by RadioterapiaHM link.springer.com/article/10.100… #radonc

Dose metrics linked to bowel toxicity for rectal RT in RAPIDO: Amazing work by Max Tanaka from NKI Medium-to-high dose volumes for bowel bag (RTOG or Embrace) best predictors for both acute & late toxicity - V30Gy for LCRT, V20Gy for short course #ESTRO25 #radonc #medphys

1/ #ESTRO2025 FAST FORWARD 10 year breast cancer results are out 40 Gy/15 fx vs 27/5 fx vs 26/5 Most women were >50y and T1N0 low risk The recurrence rate at 10y for the 26 Gy arm: 2.0% This is an INSANELY low number for risk of (any) cancer coming back To put in context:

Dr Reena Engineer from TMC Radiation Oncology presents results from Ph3 randomised POLCA-GB trial for LA Gall Bladder Ca #ASCO25 Addition of NACRT to NACT shows ✅Better response to Neoadjuvant Rx ✅Higher R0 resection rates ✅Higher EFS (4.9 Vs 10.6 mos) ✅Higher OS (10.1 Vs 21.8 mos)

📢 #ASCO25: In pts w/ 5–20 brain mets, SRS/SRT led to fewer symptoms & less functional interference vs HA-WBRT, w/ similar OS (~8.4 mo). 🔬 Phase 3 RCT (n=196) 💡 SRS/SRT = new SoC for brain mets >4? meetings.asco.org/abstracts-pres… #RadOnc #NeuroOnc #SRS #WBRT #BrainMets

🚨 POLCA-GB RCT 🇮🇳 sets new SOC for GB cancer, NACRT improves OS over NACT! #ASCO25 Huge congratulations Reena Engineer Ma'am!!! Inspiring us to explore new indications, not giving up despite all challenges 💪🏼💪🏼🏆🏆

🚨Update Randomized Trial: Significantly Better KPS & Cognitive Function with SRS compared to HA-WBRT for 5-20 brain mets 🚨🚨🚨

Finally one positive data on breast cancer for oligoprogression. Focused only on HR positive breast cancer unlike previous studies with goal to continue same systemic treatment #bcsm

Prospective Largest Study for SIB N=74 (FAST); N=280 (FAST-F) SIB Dose=33 Gy(FAST);32 Gy (Fast-F) Electrons÷207; Photons (147) SIB showed worsening Cosmesis over time